Ask AI
ProCE Banner Activity

ASC4START: Phase IIIb Trial of Asciminib vs Nilotinib in Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia

Conference Coverage
Slideset

The randomized phase IIIb ASC4START trial of asciminib vs nilotinib met its primary endpoint of longer time to treatment discontinuation due to AEs with asciminib in patients with Ph+ CML-CP.

Released: June 06, 2025

Expiration: December 05, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation